Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Genomic Medicine Sweden: Advancing precision medicine at the national level.

Journal of internal medicine·2026

Same author

Trimerization of CD40L-specific affibody molecules using collagen domains enhances target binding and CD40 blockade.

Cellular and molecular life sciences : CMLS·2026

Same author

Combining bacterial display and protein language models to engineer a CD69-binding affibody for molecular imaging of immune activation.

Protein engineering, design & selection : PEDS·2026

Same author

Engineering a conditionally active cetuximab prodrug via affibody-based paratope masking.

Journal of biological engineering·2026

Same author

Engineering affibody domains as anti-idiotypic masks for nivolumab-based prodrugs.

Protein engineering, design & selection : PEDS·2026

Same author

Preparedness for working with genomic medicine among Swedish non-genetics physicians - a nation-wide survey study.

Journal of community genetics·2026

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Engineered affinity proteins for tumour-targeting applications.

Mikaela Friedman¹, Stefan Ståhl

¹Division of Molecular Biotechnology, School of Biotechnology, AlbaNova University Center, Royal Institute of Technology (KTH), SE-106 91 Stockholm, Sweden.

Biotechnology and Applied Biochemistry

|April 4, 2009

Summary

This summary is machine-generated.

Tumor targeting using affinity proteins offers a novel approach for cancer therapy and diagnostics. These agents, including antibodies and scaffold proteins, can deliver payloads for imaging or radiotherapy, focusing on targets like EGFR and HER2.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Experiment Videos

Last Updated: Jun 24, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Area of Science:

Oncology
Biotechnology
Molecular Imaging and Radiotherapy

Background:

Tumor-associated antigen targeting is an evolving cancer treatment strategy.
Monoclonal antibodies are widely used, with over 20 approved therapies, primarily in oncology.
Advances in genetic engineering enable high-throughput generation of various affinity proteins for diagnostics and therapy.

Purpose of the Study:

To review strategies for targeting solid tumors using affinity proteins.
To discuss the delivery of radionuclides for molecular imaging or radiotherapy.
To focus on antibodies, antibody derivatives, and non-immunoglobulin scaffold proteins, including the Affibody molecule.

Main Methods:

Review of current literature on tumor-targeting affinity proteins.
Discussion of ErbB receptor family as biomarkers for tumor targeting.
Analysis of strategies for radionuclide delivery via affinity proteins.

Main Results:

Affinity proteins can alter tumor progression by affecting signal transduction or delivering payloads.
EGFR and HER2 are overexpressed in malignancies, making them key targets for solid tumors.
Various affinity proteins, including antibodies, antibody derivatives, and scaffold proteins, are investigated for in vivo diagnostics and therapy.

Conclusions:

Affinity proteins provide versatile platforms for targeted cancer therapy and molecular imaging.
The ErbB family, particularly EGFR and HER2, are significant targets for solid tumor treatment.
The Affibody molecule and other engineered proteins show promise in radionuclide-based tumor targeting strategies.